ArticleAngewandte Chemie (International ed. in English)2026
Complete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Anthracyclines including doxorubicin are cornerstone chemotherapeutic agents with high cytotoxic potency, but their use in cancer treatment is limited by irreversible dose-dependent cardiotoxicity. Recent investigations indicate that cardiotoxicity-free anthracyclines may be achieved through uncoupling DNA damage from chromatin damage. However, semi-synthetic derivatization is complicated by anthracycline structural complexity. Here, we report a modular synthetic biology platform for the complete refactoring and combinatorial biosynthesis of anthracyclines in Streptomyces coelicolor M1152ΔmatAB. Using standardized synthetic DNA parts, we refactored three full biosynthetic pathways of nogalamycin (38 genes), doxorubicin (31 genes), and aclacinomycin (31 genes). The pathways were organized into four functional modules (aglycone biosynthesis, TDP-carbohydrate formation, glycosylation, and tailoring reactions) to facilitate efficient reconstruction. The modular design facilitated streamlined combinatorial biosynthesis yielding 16 derivatives, including 13 novel analogs. Bioactivity profiling across human cancer cell lines identified six potent congeners. Their cytotoxicity correlated with in vitro DNA binding affinities. Two hit molecules harbored desired bioactivity profiles promoting histone eviction at a faster rate than doxorubicin, without causing DNA double strand breaks. Our approach highlights the power of synthetic biology in rational natural product engineering and provides a scalable strategy for exploring new and improved anthracycline anti-cancer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.